Canagliflozin is indicated for Type 2 Diabetes Mellitus. Canagliflozin was developed by Tanabe Pharma Corporation.
The API has now reached off-patent status, after being launched in 2013.

The information provided above is sourced from Chemrobotics PharmaVetPat https://chemroboticspharma.com/pharmVetPat
to find out more, including patent landscape and routes of synthesis, please contact our sales team.

According to PharmaTrade, Canagliflozin was exported from India in 2023 , with an average price over the period of $1528 /kg.
The key suppliers were Gallean Healthcare, with a focus on markets in MEA.

For enquiries regarding more detailed trade data of Canagliflozin and many others, contact info@pharmacheminvestor.com